Pharmacia & Upjohn Rescriptor
Executive Summary
Supplemental NDA approved June 14 for 200 mg tablet. Rescriptor (delavirdine), a non-nucleoside reverse transcriptase inhibitor, was previously approved as a 100 mg tablet. The 200 mg tablet, two-thirds the size of the 100 mg tablet, was designed to improve patient acceptance and compliance